Please upgrade your browser.
Funding is under the umbrella of the Congressionally Directed Medical Research Programs and supports medical research for several forms of cancer, including kidney cancer.
The U.S. Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.
The current edition of Kidney Cancer Journal is online.
Controversy exists over whether lymph node dissection (LND) simply provides improved staging or whether removal of pathologic nodes offers a therapeutic advantage.
Axitinib treatment led to a significant and clinically meaningful improvement in progression-free survival compared with sorafenib in patients with treatment-refractory renal-cell carcinoma...
Kidney Contenders Pre-Event May 2012
This single arm study will assess progression free survival, tumor response and safety of Avastin in combination with interferon alfa-2a (IFN) as first line treatment in patients with metastatic clear cell renal cell carcinoma.
The study has revealed that usually the kidney cancer patients needing surgery have their whole kidney taken out but the patients can healthily survive long-term even if just a part of the organ is removed.
The goal of this clinical research study is to learn if SutentÂ® (sunitinib malate), given before surgery, can help control renal cell carcinoma. The safety of sunitinib malate will also be studied.
This phase I trial is studying the side effects and best dose of interleukin-7 in treating patients with metastatic melanoma or locally advanced or metastatic kidney cancer.
|Powered by NeonCRM|